Ana I. Coelho

Ana I. Coelho

Auto-generated profile, based on publicly available information

Ana I. Coelho

Cardiovascular R&D Center – UnIC@RISE, Department of Surgery and Physiology, Faculty of Medicine University of Porto Porto Portugal

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2019 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
MRM. Estela Rubio-Gozalbo
M. Estela Rubio-Gozalbo
MHM. Haskovic
M. Haskovic
ABAnnet Bosch
Annet Bosch
BBBirute Burnyte
Birute Burnyte
ACA. I. Coelho
A. I. Coelho
GBGerard Berry
Gerard Berry
Classic galactosemia is a rare inborn error of carbohydrate metabolism, caused by a severe deficiency of the enzyme galactose-1-phosphate uridylyltransferase (GALT). A galactose-restricted diet has proven to be very effective to treat the neonatal life-threatening manifestations and has been the cornerstone of treatment for this severe disease. However, burdensome complications occur despite a lifelong diet. For rare diseases, a patient disease specific registry is fundamental to monitor the lifespan pathology and to evaluate the safety and efficacy of potential therapies. In 2014, the international Galactosemias Network (GalNet) developed a web-based patient registry for this disease, the GalNet Registry. The aim was to delineate the natural history of classic galactosemia based on a large dataset of patients. Observational data derived from 15 countries and 32 centers including 509 patients were acquired between December 2014 and July 2018. Most affected patients experienced neonatal manifestations (79.8%) and despite following a diet developed brain impairments (85.0%), primary ovarian insufficiency (79.7%) and a diminished bone mineral density (26.5%). Newborn screening, age at onset of dietary treatment, strictness of the galactose-restricted diet, p.Gln188Arg mutation and GALT enzyme activity influenced the clinical picture. Detection by newborn screening and commencement of diet in the first week of life were associated with a more favorable outcome. A homozygous p.Gln188Arg mutation, GALT enzyme activity of ≤ 1% and strict galactose restriction were associated with a less favorable outcome. This study describes the natural history of classic galactosemia based on the hitherto largest data set.

9 March 2017 in Journal of Inherited Metabolic Disease
Verified
Journal Article
Open access
PDF file
ACAna I. Coelho
Ana I. Coelho
MRM. Estela Rubio-Gozalbo
M. Estela Rubio-Gozalbo
Joao VicenteJoao Vicente
Joao Vicente
IRIsabel Rivera
Isabel Rivera
Classic galactosemia is a rare inherited disorder of galactose metabolism caused by deficient activity of galactose‐1‐phosphate uridylyltransferase (GALT), the second enzyme of the Leloir pathway. It presents in the newborn period as a life‐threatening disease, whose clinical picture can be resolved by a galactose‐restricted diet. The dietary treatment proves, however, insufficient in preventing severe long‐term complications, such as cognitive, social and reproductive impairments. Classic galactosemia represents a heavy burden on patients’ and their families’ lives. After its first description in 1908 and despite intense research in the past century, the exact pathogenic mechanisms underlying galactosemia are still not fully understood. Recently, new important insights on molecular and cellular aspects of galactosemia have been gained, and should open new avenues for the development of novel therapeutic strategies. Moreover, an international galactosemia network has been established, which shall act as a platform for expertise and research in galactosemia. Herein are reviewed some of the latest developments in clinical practice and research findings on classic galactosemia, an enigmatic disorder with many unanswered questions warranting dedicated research.

Verified
Journal Article
Open access
PDF file
BDBritt Delnoy
Britt Delnoy
ACAna I. Coelho
Ana I. Coelho
MRM. Estela Rubio-Gozalbo
M. Estela Rubio-Gozalbo
Type I (classic) galactosemia, galactose 1-phosphate uridylyltransferase (GALT)-deficiency is a hereditary disorder of galactose metabolism. The current therapeutic standard of care, a galactose-restricted diet, is effective in treating neonatal complications but is inadequate in preventing burdensome complications. The development of several animal models of classic galactosemia that (partly) mimic the biochemical and clinical phenotypes and the resolution of the crystal structure of GALT have provided important insights; however, precise pathophysiology remains to be elucidated. Novel therapeutic approaches currently being explored focus on several of the pathogenic factors that have been described, aiming to (i) restore GALT activity, (ii) influence the cascade of events and (iii) address the clinical picture. This review attempts to provide an overview on the latest advancements in therapy approaches.

23 June 2014 in Molecular Genetics & Genomic Medicine
Verified
Journal Article
Open access
PDF file
ACAna I. Coelho
Ana I. Coelho
MTMatilde Trabuco
Matilde Trabuco
RRRuben Ramos
Ruben Ramos
MSMaria João Silva
Maria João Silva
IAIsabel Tavares de Almeida
Isabel Tavares de Almeida
Joao VicenteJoao Vicente
Joao Vicente
Galactose‐1‐phosphate uridylyltransferase (GALT) is a key enzyme in galactose metabolism, particularly important in the neonatal period due to ingestion of galactose‐containing milk. GALT deficiency results in the genetic disorder classic galactosemia, whose pathophysiology is still not fully elucidated. Whereas classic galactosemia has been hypothesized to result from GALT misfolding, a thorough functional–structural characterization of GALT most prevalent variants was still lacking, hampering the development of alternative therapeutic approaches. The aim of this study was to investigate the structural–functional effects of nine GALT mutations, four of which account for the vast majority of the mutations identified in galactosemic patients. Several methodologies were employed to evaluate the mutations' impact on GALT function, on the protein secondary and tertiary structures, and on the aggregation propensity. The major structural effect concerns disturbed propensity for aggregation, particularly striking for the p.Q188R variant, resulting from the most frequent (~60%) allele at a worldwide scale. The absence of major effects at the secondary and tertiary structure levels suggests that the disturbed aggregation results from subtle perturbations causing a higher and/or longer exposure of hydrophobic residues in the variants as compared to WT GALT. The results herein described indicate a possible benefit from introducing proteostasis regulators and/or chemical/pharmacological chaperones to prevent the accumulation of protein aggregates, in new avenues of therapeutic research for classic galactosemia.

14 September 2017 in Journal of Inherited Metabolic Disease
Verified
Journal Article
Open access
PDF file
JVJo M. Vanoevelen
Jo M. Vanoevelen
BEBritt van Erven
Britt van Erven
JBJörgen Bierau
Jörgen Bierau
XHXiaoping Huang
Xiaoping Huang
GBGerard T. Berry
Gerard T. Berry
MRM. Estela Rubio-Gozalbo
M. Estela Rubio-Gozalbo
Classic galactosemia is a genetic disorder of galactose metabolism, caused by severe deficiency of galactose‐1‐phosphate uridylyltransferase (GALT) enzyme activity due to mutations of the GALT gene. Its pathogenesis is still not fully elucidated, and a therapy that prevents chronic impairments is lacking. In order to move research forward, there is a high need for a novel animal model, which allows organ studies throughout development and high‐throughput screening of pharmacologic compounds. Here, we describe the generation of a galt knockout zebrafish model and present its phenotypical characterization. Using a TALEN approach, a galt knockout line was successfully created. Accordingly, biochemical assays confirm essentially undetectable galt enzyme activity in homozygotes. Analogous to humans, galt knockout fish accumulate galactose‐1‐phosphate upon exposure to exogenous galactose. Furthermore, without prior exposure to exogenous galactose, they exhibit reduced motor activity and impaired fertility (lower egg quantity per mating, higher number of unsuccessful crossings), resembling the human phenotype(s) of neurological sequelae and subfertility. In conclusion, our galt knockout zebrafish model for classic galactosemia mimics the human phenotype(s) at biochemical and clinical levels. Future studies in our model will contribute to improved understanding and management of this disorder.

23 July 2014 in European Journal of Human Genetics
Verified
Journal Article
Closed access
ACAna I Coelho
Ana I Coelho
SLSílvia Lourenço
Sílvia Lourenço
MTMatilde Trabuco
Matilde Trabuco
MSMaria João Silva
Maria João Silva
AOAnabela Oliveira
Anabela Oliveira
IRIsabel Rivera
Isabel Rivera